Sanofi
SAN
Pozycja w akcjach
#225
Sanofi is a global healthcare enterprise dedicated to the research,... Sanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a portfolio of established prescription drugs. Through its Vaccines division, Sanofi supplies crucial immunizations, including pediatric vaccines for diseases like poliomyelitis, pertussis, and Hib, alongside adult vaccines addressing influenza, booster needs, meningitis, and those required for travel or endemic regions. The Consumer Healthcare portfolio features over-the-counter remedies for common ailments such as allergies, coughs and colds, and pain relief. It also includes products for liver care, general physical and mental wellness, probiotics, digestive health, and nutritional support. Additionally, this segment offers personal care items like daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema. Sanofi maintains an active pipeline with numerous pharmaceutical products and vaccines currently undergoing various stages of development. The company has forged strategic alliances, including a collaboration with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company operated as Sanofi-Aventis before rebranding to Sanofi in May 2011.
Cena akcji
$83.84
Kapitalizacja rynkowa
$100.45B
Zmiana (1 dzień)
1.48%
Zmiana (1 rok)
-16.74%
Kraj
FR
Handel Sanofi (SAN)
Kategoria
Healthcare
Przychody dla Sanofi (SAN)
Przychody w Oct 2026 TTM: 0
Według najnowszych raportów finansowych Sanofi, obecny przychód firmy (TTM) wynosi 0. W roku 2026 firma osiągnęła przychód w wysokości 0 równa się przychodu z roku 2026, który wynosił 0. Przychód to całkowita kwota dochodu generowana przez firmę ze sprzedaży towarów lub usług. W przeciwieństwie do zysku, nie są odliczane żadne koszty.
Historia przychodów firmy Sanofi od 2001 do 2026
Przychody na koniec każdego roku
| Rok | Przychody | Zmień |
|---|---|---|
| 2025 | $54.81B | 18.94% |
| 2024 | $46.08B | 1.40% |
| 2023 | $45.44B | 5.12% |
| 2022 | $43.23B | -2.95% |
| 2021 | $44.55B | -2.12% |
| 2020 | $45.51B | 7.79% |
| 2019 | $42.22B | 2.98% |
| 2018 | $41.00B | -5.67% |
| 2017 | $43.46B | 19.05% |
| 2016 | $36.51B | -3.56% |
| 2015 | $37.85B | -2.23% |
| 2014 | $38.72B | -10.02% |
| 2013 | $43.03B | -9.28% |
| 2012 | $47.43B | 4.51% |
| 2011 | $45.38B | 5.96% |
| 2010 | $42.83B | -2.86% |
| 2009 | $44.09B | 9.79% |
| 2008 | $40.16B | -6.08% |
| 2007 | $42.76B | 10.20% |
| 2006 | $38.80B | 15.26% |
| 2005 | $33.66B | 65.16% |
| 2004 | $20.38B | 101.47% |
| 2003 | $10.12B | 29.32% |
| 2002 | $7.82B | 35.65% |
| 2001 | $5.77B | 0.00% |
Przychody podobnych firm lub konkurentów
| Firma | Przychody | Różnica w przychodach | Kraj |
|---|---|---|---|
| $79.67B | - |
US
|
|
| $99.34B | - |
US
|
|
| $64.39B | - |
US
|
|
| $66.40B | - |
US
|
|
| $77.52B | - |
CH
|
